EFA vs XBI
iShares MSCI EAFE ETF vs SPDR S&P Biotech ETF
- • EFA has the lower expense ratio at 0.32% vs 0.35% for XBI.
- • EFA pays a higher dividend yield (3.17%).
Side-by-side metrics
| Metric | EFA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.32% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.17% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $75.61B | $8.30B |
YTD return | 9.14% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.89 | 1.09 |
P/E ratio | 18.21 | — |
Last price | $102.89 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
EFA top holdings
| ASML.AS | ASML Holding NV | 2.48% |
| HSBA.L | HSBC Holdings PLC | 1.44% |
| AZN.L | AstraZeneca PLC | 1.36% |
| ROP.SW | Roche Holding AG Ordinary Shares new | 1.33% |
| NOVN.SW | Novartis AG Registered Shares | 1.29% |
| NESN.SW | Nestle SA | 1.22% |
| SHEL.L | Shell PLC | 1.18% |
| SIE.DE | Siemens AG | 1.04% |
| CBA.AX | Commonwealth Bank of Australia | 0.98% |
| 8306.T | Mitsubishi UFJ Financial Group Inc | 0.95% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About EFA
EFA (iShares MSCI EAFE ETF) is Developed-market equities outside US/Canada. Managed by iShares, the fund carries $75.6B in assets under management, an expense ratio of 0.32%, a dividend yield of 3.17%. Its largest holding is ASML Holding NV (ASML.AS), which represents 2.5% of the portfolio. Real Estate is the fund's largest sector exposure at 1.9%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.